Success Metrics

Clinical Success Rate

100.0%

Based on 3 completed trials

Completion Rate

100%(3/3)

Active Trials

4(50%)

Results Posted

167%(5 trials)

Phase Distribution

Ph phase_2

38%

Ph phase_3

63%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Phase 2Efficacy & side effects

3(37.5%)

Phase 3Large-scale testing

5(62.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(4)

Completed(3)

Other(1)

Detailed Status

Active, not recruiting4

Completed3

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 23 (37.5%)

Phase 35 (62.5%)

Trials by Status

unknown113%

active_not_recruiting450%

completed338%

Recent Activity

4 active trials

Showing 5 of 8

active_not_recruitingphase_3

Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)

NCT02542293

active_not_recruitingphase_3

Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

NCT02453282

completedphase_3

Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer

NCT03519971

active_not_recruitingphase_3

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

NCT03003962

active_not_recruitingphase_3

Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).

NCT03164616

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT02542293Phase 3

Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)

Active Not Recruiting

NCT02453282Phase 3

Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

Active Not Recruiting

NCT03519971Phase 3

Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer

Completed

NCT03003962Phase 3

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

Active Not Recruiting

NCT03164616Phase 3

Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).

Active Not Recruiting

NCT03809637Phase 2

A Study of Pemetrexed Plus Cisplatin in Patients With Refractory Soft Tissue Sarcoma

Completed

NCT04982549Phase 2

A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC

Unknown

NCT00744900Phase 2

Pemetrexed Plus Cisplatin for Brain Metastasis of Advanced Non - Small Cell Lung Cancer (NSCLC)

Completed

All 8 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 8